Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
CEINGE Advanced Biotechnologies, 80131 Naples, Italy.
Int J Mol Sci. 2020 Sep 12;21(18):6682. doi: 10.3390/ijms21186682.
Sudden cardiac death (SCD) is a devastating event which can also affect people in apparent good health, such as young athletes. It is known that intense and continuous exercise along with a genetic background that predisposes a person to the risk of fatal arrhythmias is a trigger for SCD. Therefore, knowledge of the athlete's genetic conditions underlying the onset of SCD must be extended, in order to develop new effective prevention and/or therapeutic strategies. Arrhythmic features occur across a broad spectrum of cardiac diseases, sometimes presenting with overlapping phenotypes. The genetic basis of arrhythmogenic disorders has been greatly highlighted in the last 30 years, and has shown marked heterogeneity. The advent of next-generation sequencing has constantly updated our understanding of the genetic basis of arrhythmogenic diseases and is laying the foundation for precision medicine. With the exception of a few clinical cases involving a single athlete showing a highly suspected phenotype for the presence of a heart disease, there are few studies to date that analysed the applicability of genetic testing on cohorts of athletes. This evidence shows that genetic testing can contribute to the diagnosis of up to 13% of athletes; however, the presence of clinical markers is essential. This review aims to provide a reference collection on current knowledge of the genetic basis of sudden cardiac death in athletes and to review updated evidence on the effectiveness of genetic testing in early identification of athletes at risk for SCD.
心源性猝死(SCD)是一种毁灭性的事件,也可能影响到看似健康的人,如年轻运动员。众所周知,剧烈和持续的运动以及使个体易患致命性心律失常的遗传背景是 SCD 的触发因素。因此,必须扩展对导致 SCD 的运动员遗传条件的了解,以便制定新的有效预防和/或治疗策略。心律失常特征出现在广泛的心脏疾病中,有时表现出重叠的表型。心律失常性疾病的遗传基础在过去 30 年中得到了极大的强调,并表现出明显的异质性。下一代测序的出现不断更新了我们对心律失常性疾病遗传基础的理解,并为精准医学奠定了基础。除了极少数涉及单个运动员的临床病例表现出高度怀疑存在心脏病的高度可疑表型外,迄今为止,很少有研究分析了对运动员队列进行基因检测的适用性。这一证据表明,基因检测可以帮助诊断高达 13%的运动员;然而,临床标志物的存在是必不可少的。本综述旨在提供关于运动员心源性猝死遗传基础的最新知识参考,并回顾基因检测在早期识别 SCD 风险运动员方面的有效性的最新证据。